DCF Advisers’s AnaptysBio ANAB Stock Holding History

DCF Advisers’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$615K	Sell	9,114 -9,661	-51%	-$586K	0.11%	79
2026 Q1	$1.04M	Sell	18,775 -16,475	-47%	-$886K	0.28%	59
2025 Q4	$1.71M	Sell	35,250 -12,750	-27%	-$497K	0.46%	54
2025 Q3	$1.47M	Hold	48,000	–	–	0.47%	54
2025 Q2	$1.07M	Buy	48,000 +13,150	+38%	+$275K	0.49%	52
2025 Q1	$648K	Buy	+34,850	New	+$581K	0.31%	64

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DCF Advisers's ANAB Position: Q2 2026 in Review

DCF Advisers reduced its AnaptysBio (ANAB) stake by 51% in Q2 2026, selling an estimated $586K and leaving 9,114 shares worth $615K. The position accounts for 0.11% of the portfolio, ranked #79.

DCF Advisers first reported a position in ANAB in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.71M in Q4 2025. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

DCF Advisers held 9,114 shares of AnaptysBio worth $615K as of Q2 2026.
DCF Advisers sold 9,661 AnaptysBio shares in Q2 2026, an estimated $586K.
AnaptysBio made up 0.11% of DCF Advisers's portfolio in Q2 2026, its #79 holding.
DCF Advisers first reported a position in AnaptysBio in Q1 2025 and has held it in 6 quarters since.
DCF Advisers's AnaptysBio position peaked at $1.71M in Q4 2025.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.